Anastrozole: Nursing Drug Guide, Bone Loss & Fracture Risk & NCLEX Review
Aromatase inhibition cuts estrogen in postmenopausal breast cancer—but on shift your priority is bone mineral density loss, fracture and fall prevention, and ischemic cardiovascular vigilance when the patient already has coronary disease.
Anastrozole suppresses aromatase and lowers circulating estrogen. ARIMIDEX labeling warns that decreases in bone mineral density (BMD) may occur and that fracture rates were higher with anastrozole than tamoxifen in the ATAC adjuvant trial (10% vs 7% all fractures). Because estrogen supports bone strength, nurses must monitor for new bone pain, implement fall precautions, and ensure BMD follow-up per prescriber plan. In women with pre-existing ischemic heart disease, ischemic cardiovascular events occurred in 17% on anastrozole versus 10% on tamoxifen—assess chest pain and anginal symptoms aggressively and coordinate cardiology input when indicated. Anastrozole is contraindicated in pregnancy and in patients with hypersensitivity (including anaphylaxis).
📋 Contents
⚡ Quick facts
💡 Key takeaway
Anastrozole is not just a daily tablet on the MAR—it chronically lowers estrogen and can erode bone mineral density over months to years. Track baseline and follow-up BMD, teach fall prevention, and treat new bone pain or post-fall injury as a medication-related safety event until evaluated—not routine aging.
Most common brand names
Anastrozole is available as a generic tablet and under the brand name Arimidex (AstraZeneca). Verify the MAR matches the dispensed product—strength is 1 mg per tablet across labeled formulations.
Do not confuse anastrozole with other breast cancer endocrine agents (tamoxifen, exemestane, letrozole) or with similarly named products on the MAR. Anastrozole is a nonsteroidal aromatase inhibitor used in postmenopausal hormone receptor–positive breast cancer pathways per ARIMIDEX prescribing information.
Why we give it — Indications
Anastrozole is indicated for postmenopausal women with hormone-driven breast cancer. It is not effective in premenopausal endocrine status and offers no clinical benefit in that population per labeling.
| Use | Detail |
|---|---|
| Adjuvant therapy | Adjuvant treatment of postmenopausal women with hormone receptor–positive early breast cancer (ATAC trial basis). |
| First-line advanced disease | First-line treatment of postmenopausal women with hormone receptor–positive or hormone receptor–unknown locally advanced or metastatic breast cancer. |
| Second-line after tamoxifen | Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. ER-negative patients and those who did not respond to prior tamoxifen rarely responded to anastrozole in labeling. |
On a small screen, swipe or scroll sideways to see the full table.
How it works
In postmenopausal women, estrogens are formed mainly when aromatase converts adrenal androgens to estrone and estradiol. Anastrozole is a selective nonsteroidal aromatase inhibitor that significantly lowers serum estradiol concentrations without detectable effects on adrenal corticosteroids or aldosterone per ARIMIDEX labeling.
The recommended 1 mg daily dose reduced estradiol by approximately 70% within 24 hours and about 80% after 14 days of dosing. Because estrogen supports bone mineral density, chronic suppression is the pharmacologic basis for BMD loss, higher fracture rates versus tamoxifen, and the need for bone monitoring and fall precautions throughout therapy.
Dosing overview
The dose of ARIMIDEX is one 1 mg tablet once daily. For advanced breast cancer, continue until tumor progression. For adjuvant early breast cancer, optimal duration is unknown; the ATAC trial administered anastrozole for five years.
Before you give it — Safety check
Pretreatment checks
- Confirm postmenopausal status and hormone receptor context; verify not pregnant or planning pregnancy
- Review history of ischemic heart disease, prior myocardial infarction, or recurrent angina
- Baseline and prior BMD results, fracture history, fall risk, calcium/vitamin D supplementation plan
- Allergy history—prior hypersensitivity to anastrozole or excipients (lactose, etc.)
Contraindications
- Women of premenopausal endocrine status, including pregnancy—may cause fetal harm; no clinical benefit in premenopausal breast cancer per labeling
- Demonstrated hypersensitivity to anastrozole or any excipient; observed reactions include anaphylaxis, angioedema, and urticaria
Important interactions and combination rules
| Drug / product | Effect | Nursing action |
|---|---|---|
| Tamoxifen | Do not use in combination—no additional benefit over tamoxifen monotherapy per ARIMIDEX labeling | Verify MAR shows only one endocrine agent unless prescriber explicitly transitions therapy; clarify during medication reconciliation |
| Estrogen-containing products | May diminish anastrozole activity (HRT, oral contraceptives, vaginal estrogen unless approved) | Ask about patches, rings, and OTC estrogen creams at every visit; notify prescriber/pharmacist if combined use suspected |
| Warfarin | ATAC trial: no clinically significant interaction observed with warfarin | Continue routine anticoagulation monitoring per prescriber orders—do not assume interaction-driven INR changes |
On a small screen, swipe or scroll sideways to see the full table.
In women with pre-existing ischemic heart disease, ischemic cardiovascular events occurred in 17% on anastrozole versus 10% on tamoxifen in ATAC. Weigh risks and benefits with the prescriber; assess chest pain, dyspnea, and exertional symptoms at each encounter.
Administration
Route: Oral tablet, 1 mg once daily. ARIMIDEX may be taken with or without food per labeling.
- Swallow tablet whole with water; verify correct daily dose—there is no split-dose regimen
- Give at the same time each day when possible to support adherence for long adjuvant courses
- Do not restart after hypersensitivity reaction without prescriber and allergy review
- Store at controlled room temperature per product labeling; protect from moisture
Expected therapeutic response
Therapeutic success in breast cancer endocrine therapy is measured over months to years—not by immediate symptom relief. Nurses support monitoring for disease stability, tolerability, and long-term safety rather than expecting rapid pain resolution.
- Adjuvant setting: continued hormone blockade per oncology plan; absence of locoregional recurrence or new metastatic symptoms per prescriber follow-up
- Advanced setting: continued therapy until tumor progression per prescriber
- Assess aromatase-inhibitor musculoskeletal symptoms with structured pain assessment—joint stiffness may appear even when cancer is controlled
Red flags — When to escalate
- New or worsening bone pain, especially axial or focal pain suggesting fracture or metastasis—notify prescriber same day
- Fall with injury, deformity, inability to bear weight, or suspected hip/wrist/spine fracture—urgent imaging and orthopedic/oncology pathway per protocol
- Chest pain, pressure, dyspnea on exertion, or syncope in a patient with ischemic heart disease history—urgent cardiovascular evaluation
- Facial/laryngeal swelling, difficulty breathing, or urticaria after a dose—stop drug and treat as anaphylaxis per emergency protocol
- Signs of cholestasis or hepatitis (jaundice, dark urine, RUQ pain, severe fatigue)—notify prescriber; serious hepatic reactions are reported rarely post-marketing
Common and serious adverse effects
In ATAC (>10% incidence), common anastrozole adverse reactions included hot flashes, asthenia, arthritis, pain, arthralgia, hypertension, rash, osteoporosis, fractures, back pain, insomnia, headache, peripheral edema, and lymphedema regardless of causality.
| Category | Examples (labeling) | Nursing focus |
|---|---|---|
| Musculoskeletal / bone | Arthralgia, arthritis, joint pain, bone pain, osteoporosis, fractures (10% anastrozole vs 7% tamoxifen all fractures in ATAC) | Fall precautions, BMD monitoring, calcium/vitamin D adherence, prompt evaluation of new bone pain |
| Vasomotor / mood | Hot flashes (most common reason for discontinuation in ATAC, though fewer stopped anastrozole than tamoxifen for this), insomnia, depression, anxiety | Nonpharmacologic cooling strategies, sleep hygiene, mood screening, prescriber referral when function impaired |
| Cardiovascular / metabolic | Hypertension; elevated cholesterol (9% anastrozole vs 3.5% tamoxifen in ATAC); ischemic CV events higher with pre-existing ischemic heart disease | BP monitoring, lipid follow-up, anginal symptom teaching |
| Serious (<1 in 10,000) | Skin lesions/ulcers/blisters; allergic reactions with face/lip/tongue/throat swelling; liver inflammation with jaundice or malaise | Stop drug, emergency care for airway compromise, notify prescriber for hepatic or severe skin findings |
On a small screen, swipe or scroll sideways to see the full table.
Overdose and toxicity
Clinical trials administered ARIMIDEX up to 60 mg as a single dose in healthy male volunteers and up to 10 mg daily in postmenopausal women with advanced breast cancer; these dosages were tolerated. A single life-threatening dose threshold has not been established.
Management
- No specific antidote—treatment must be symptomatic per ARIMIDEX overdosage section
- Consider that multiple agents may have been ingested; induce vomiting only if patient is alert and per poison-control guidance
- Dialysis may be helpful because anastrozole is not highly protein bound (40% bound)
- General supportive care with frequent vital sign monitoring and close observation
Contact local poison control or medical toxicology services per facility protocol for suspected overdose—even when the patient appears well.
Look-alike / sound-alike and error prevention
- Anastrozole vs letrozole vs exemestane—all aromatase inhibitors but not interchangeable; verify exact drug on MAR
- Anastrozole vs tamoxifen—different class and interaction profile; never administer both concurrently per labeling
- Arimidex vs similarly named oncology agents—read full generic name on blister packs and home bottles
- 1 mg daily—confirm no duplicate endocrine rows on MAR after clinic or telehealth updates
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Food timing | May take with or without food; consistency helps adherence |
| Crush/split | Swallow whole film-coated tablet unless pharmacy confirms alternate formulation for enteral tube |
| Duration | Adjuvant courses may extend multiple years—teach long-term bone and CV monitoring expectations |
| Home supply | Verify patient is not also taking estrogen products or duplicate AI prescriptions from outside providers |
| Commonly missed | Fall risk in outpatient oncology—many fractures occur outside the hospital |
| Ask pharmacy when | Drug interaction questions, severe hepatic impairment, enteral administration, or suspected overdose |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Osteopenia / osteoporosis / prior fracture | ATAC bone substudy: mean decreases in lumbar spine and total hip BMD versus baseline; fracture rate 10% with anastrozole vs 7% tamoxifen. Highest nursing priority for fall precautions and BMD surveillance. |
| Pre-existing ischemic heart disease | Ischemic cardiovascular events 17% anastrozole vs 10% tamoxifen in ATAC—consider risks and benefits before starting; monitor anginal symptoms. |
| Premenopausal or pregnant patients | Contraindicated in pregnancy; no benefit in premenopausal breast cancer—verify menopausal status. |
| Severe hepatic impairment | Not studied in severe hepatic impairment—use caution; rare serious hepatic reactions reported post-marketing. |
| Hypersensitivity history | Contraindicated if prior anastrozole hypersensitivity; reactions may include anaphylaxis, angioedema, urticaria per labeling. |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Bone mineral density with bone density scan (DEXA) per oncology plan—labeling states BMD decreases may occur and monitoring should be considered
- New bone pain, falls, fractures, and functional mobility—especially during years 1–3 of adjuvant therapy
- Blood pressure and ischemic symptoms in patients with coronary disease; lipid changes—trend lipid panel per prescriber (elevated cholesterol reported more often vs tamoxifen in ATAC)
- Vasomotor symptoms, mood, sleep, and adherence over long courses
Document
- Dose, time, and patient-reported adherence; hold events after fracture or hypersensitivity
- DEXA dates, T-scores, calcium/vitamin D and bone-protective therapy orders
- Fall-risk screening, home safety teaching, and prescriber notification for new skeletal or cardiac symptoms
Patient teaching
- Anastrozole lowers estrogen to treat breast cancer but also weakens bones over time—report new bone pain or any fall with injury immediately
- Take 1 mg daily at about the same time; do not double doses; do not take estrogen products unless the oncology team approves
- Continue calcium and vitamin D if prescribed; keep DEXA appointments; use fall precautions at home (lighting, rugs, assistive devices)
- Report chest pressure, shortness of breath on exertion, or arm/jaw pain if you have heart disease history
- Seek emergency care for facial swelling, trouble breathing, or severe rash after a dose
- For suspected overdose, contact local poison control or emergency services per your facility guidance—there is no specific antidote; supportive care is used
The Hold Rule
Do not give and contact the prescriber or pharmacist when:
- Suspected pregnancy or premenopausal status not cleared by prescriber
- Known hypersensitivity, anaphylaxis, angioedema, or serious allergic reaction after prior dose
- Acute fracture, fall with injury, or new focal bone pain until imaging and prescriber/oncology plan clarify whether to continue therapy
- New or worsening angina, chest pain, or ischemic symptoms in a patient with pre-existing ischemic heart disease
- Suspected overdose or ingestion of extra tablets—hold and initiate supportive-care pathway per protocol
Hold parameters may vary by institutional protocol. Follow oncology, cardiology, and pharmacy guidance for bone-protective therapy and endocrine continuation decisions.
Clinical practice integration and workflow
Anastrozole is a once-daily oral agent, but its safety story is longitudinal: estrogen suppression drives bone loss and fracture risk across years of adjuvant therapy, while cardiovascular events deserve extra vigilance when ischemic heart disease is already present.
1. Pre-administration cue scan
- Confirm postmenopausal status, correct 1 mg dose, and no duplicate aromatase inhibitor or concurrent tamoxifen on MAR
- Review last DEXA, fracture history, fall-risk score, and whether calcium/vitamin D or bone-protective therapy is active
- Ask about new bone pain, recent falls, chest pain, or estrogen product use since last visit
2. Safety classification
Not a universal high-alert medicationTreat as high-stakes chronic therapy for skeletal and cardiovascular surveillance—fracture prevention and ischemic symptom recognition are core nursing responsibilities per ARIMIDEX labeling.
3. Medication reconciliation touchpoints
- At admission, clinic intake, and discharge, reconcile endocrine therapy so anastrozole is neither omitted nor duplicated
- Flag estrogen patches, vaginal estrogen, or duplicate AI prescriptions from outside oncology
4. Teach-back prompts
- “What bone or fall symptoms should you report between visits?”
- “Why should you keep DEXA and calcium/vitamin D plans even when you feel well?”
5. Care coordination
Oncology / prescriber: BMD trends, fracture events, therapy duration, and benefit–risk when skeletal toxicity emerges.
Pharmacist: Drug interactions, hold rules after injury, and overdose supportive-care guidance.
Cardiology: New angina or ischemic symptoms in patients with pre-existing coronary disease.
🧠 Quick mental checklist
- When is the next DEXA due, and did the last T-score decline?
- Any new bone pain, fall, or fracture since the last visit?
- Is the patient on calcium/vitamin D or bone-protective therapy per plan?
- Does this patient have ischemic heart disease—and any new chest pain today?
- Is only one endocrine agent on the MAR (no tamoxifen plus anastrozole)?
Anastrozole NCLEX practice questions
Practice NCLEX-style clinical judgment practice for anastrozole using a tabbed outpatient case (MAR · Labs · History · Nursing notes) focused on bone loss and fracture risk, then work through priority action, SATA cue recognition, BMD trend interpretation, ordered post-fall steps, overdose-management cloze, and matrix urgency sorting—recognise cues → analyse → prioritise → act → evaluate outcomes.
Unfolding case. Diane is a 68-year-old with hormone receptor–positive breast cancer on anastrozole 1 mg daily for 18 months. She has pre-existing ischemic heart disease and prior osteopenia. This morning she slipped on a wet kitchen floor and now has right wrist pain with visible deformity. Oncology clinic staff ask you to review the case tabs before the next dose.
Select a tab to view MAR, labs, history, and nursing note details for this case.
- Anastrozole 1 mg PO daily at 0800 — due today; held after fall pending prescriber
- Calcium carbonate 500 mg PO BID with meals
- Cholecalciferol 1000 units PO daily
- No bisphosphonate on MAR yet
- DEXA 12 months ago: lumbar spine T-score −1.6 (osteopenia)
- DEXA today (preliminary): lumbar spine T-score −2.2 (worsening)
- Lipid panel last visit: total cholesterol 228 mg/dL (elevated vs prior year)
- Wrist X-ray ordered; not yet resulted
- Postmenopausal; adjuvant anastrozole after lumpectomy and radiation
- Myocardial infarction 2015 — pre-existing ischemic heart disease
- Prior wrist fracture none; mother had hip fracture at age 72
- Reports manageable hot flashes; denies estrogen use
- 0900: Fall in kitchen; right wrist swollen and deformed; neurovascular intact distally
- 0915: Anastrozole held; prescriber notified by phone—awaiting callback
- 0930: Patient rates wrist pain 8/10; denies chest pain; using sling from first aid
Answer key & rationale
Frequently asked questions
Why does anastrozole increase fracture risk in breast cancer patients?
Anastrozole suppresses aromatase and lowers circulating estrogen. Estrogen supports bone mineral density; ARIMIDEX labeling reports mean decreases in lumbar spine and total hip BMD in the ATAC bone substudy, and higher all-fracture rates versus tamoxifen (10% vs 7%). Nurses should monitor BMD, reinforce fall precautions, and escalate new bone pain or post-fall injury.
Should nurses monitor bone density during anastrozole therapy?
Yes. Labeling states that decreases in bone mineral density may occur and that BMD monitoring should be considered. Coordinate DEXA timing with oncology, document T-scores, and notify the prescriber when results decline or the patient reports falls or new bone pain.
When should a nurse hold anastrozole and contact the prescriber?
Hold for suspected pregnancy, known hypersensitivity or anaphylaxis, new ischemic chest pain in a patient with ischemic heart disease, suspected serious allergic reaction, or acute fracture or fall injury until the prescriber clarifies whether to continue therapy and what bone-protective measures are needed.
Is there an antidote for anastrozole overdose?
No. ARIMIDEX overdosage labeling states there is no specific antidote and treatment must be symptomatic. Provide general supportive care with frequent vital sign monitoring and close observation. Induced emesis may be considered if the patient is alert; dialysis may be helpful because anastrozole is not highly protein bound.
Can premenopausal women receive anastrozole?
No. ARIMIDEX is contraindicated in women who are or may become pregnant and offers no clinical benefit to premenopausal women with breast cancer. Verify menopausal status before administration.
What cardiovascular warning applies to anastrozole?
In women with pre-existing ischemic heart disease, labeling reports increased ischemic cardiovascular events versus tamoxifen in ATAC (17% vs 10%). Consider risks and benefits before starting therapy and monitor for angina or other ischemic symptoms during treatment.
References
-
U.S. National Library of Medicine. ARIMIDEX (anastrozole) tablet — prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4fee8d4c-bb21-4773-b622-87f9a4ff333a
-
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer.https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1419
-
National Library of Medicine. Anastrozole. Drugs and Lactation Database (LactMed).https://www.ncbi.nlm.nih.gov/books/NBK611179/
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.